The periprocedural management of patients with atherosclerotic coronary heart disease, including those who have heart disease and those who are undergoing percutaneous coronary intervention and stent placement who might require temporary interruption of platelet-directed pharmacotherapy for the purpose of an elective endoscopic gastrointestinal procedure, is a common clinical scenario in daily practice. Herein, we summarize the available information that can be employed for making management decisions and provide general guidance for risk assessment.
This article has been copublished in the 8 December 2009 issue of the Journal of the American College of Cardiology.
© 2009 by the American College of Cardiology Foundation. Reprinted with permission from the American College of Cardiology Foundation.
1Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA; 2University of Michigan, Ann Arbor, Michigan, USA; 3University of Vermont, Burlington, Vermont, USA; 4McMaster University, Hamilton, Ontario, Canada; 5Durham VA Medical Center, Durham, North Carolina, USA; 6Brigham and Women's Hospital, Boston, Massachusetts, USA; 7Eastern Virginia School of Medicine, Norfolk, Virginia, USA; 8Chinese University of Hong Kong, Hong Kong, China; 9Baylor College of Medicine, Houston, Texas, USA; 10National University of Ireland at Cork, Cork, Ireland. 11These authors contributed equally to this paper. For full author disclosures, please see the end of this article. Correspondence: Richard C. Becker, MD, Duke Clinical Research Institute, Cardiovascular Medicine, 2400 Pratt Street, Terrace Level, Room 0311, Durham, North Carolina 27705, USA. E-mail: email@example.com